Why Immuneering Corporation’s (IMRX) Stock Is Down 5.50%
As of Friday, July 10, Immuneering Corporation’s IMRX share price has dipped by 5.50%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Commentary & Analysis
Why Immuneering Corporation’s (IMRX) Stock Is Up 8.43%
As of Wednesday, July 08, Immuneering Corporation’s IMRX share price has surged by 8.43%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Immuneering Corporation’s (IMRX) Stock Is Up 5.04%
As of Monday, June 29, Immuneering Corporation’s IMRX share price has surged by 5.04%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Immuneering Corporation’s (IMRX) Stock Is Up 7.80%
As of Wednesday, June 17, Immuneering Corporation’s IMRX share price has surged by 7.80%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Immuneering Corporation’s (IMRX) Stock Is Down 5.69%
As of Friday, June 05, Immuneering Corporation’s IMRX share price has dipped by 5.69%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | IMRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $267.2 | $252.6 | 30% |
|
| Shares Out (Mil) | 64.7 | 52.3 | 54% |
|
| Institutional Ownership | 76.9% | 92.1% | 47% |
|
| Float (Mil) | 49.2 | 40.2 | 47% |
|
| Beta | 0.36 | 0.95 | 20% |
|
| Avg Daily Volume (000s) | 645 | 455 | 63% |
|
| Price Change (52-week) |
13.8% | 52.9% | 56% |
|
| Growth | IMRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (26.9%) | (9.9%) | 15% |
|
| EPS (5yr) | 18.0% | 16.0% | 64 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (14.9%) | (15.6%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.269) | ($1.113) | ($1.286) | |
| Month Ago EPS | ($0.273) | ($1.137) | ($1.338) | |
| # Rev Up | 2 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.284) | ($1.187) | ($1.353) | |
| Year/Year Chg | 29.3% | (12.6%) | (7.7%) | |
| Financials | IMRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($54) | ($43) | 15% |
|
| EPS (TTM) | ($1.061) | ($1.600) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($50) | ($31) | 9% |
|
| Net Cash Flow (TTM) (Mil) | $12 | $5 | 59% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $5 | 22% |
|
| Enterprise Value (Q1) (Mil) | $154 | $180 | 24% |
|
| Valuation | IMRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.29 | 2.56 | 33% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | IMRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (41.0%) | (49.8%) | 14% |
|
| ROE | (43.8%) | (55.5%) | 16% |
|
| Liabilities to Assets | 3.9% | 30.3% | 2% |
|
| F-Score | 3 | 3 | 19% |
|
Immuneering Corporation did not pass any screens on 7/31/2026.
